NCT04161053View on ClinicalTrials.gov

Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy

PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

November 30, 2028

Study Completion Date

December 31, 2028

Conditions
Hepatic Encephalopathy
Interventions
DRUG

Rifaximin

Rifaximin 550 mg twice daily for 6 months

DRUG

Nitazoxanide

Nitazoxanide 500 mg twice daily for 6 months

Trial Locations (1)

Unknown

RECRUITING

Sherief Abd-Elsalam, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT04161053 - Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter